survey endocrinologist updat
model
expect annual us cgm volum growth
multipl signific market
libr gain share remain
favorit long term cgm play best
pipelin industri verili
us pump market growth stabl msd-hsd
remain clear market leader
favorit idea clear path
exceed consensu expect
forese futur medicar reimburs
huge catalyst among mani
click enter text
survey us endocrinologist indic us cgm volum growth
 gain cgm share maintain
share posit price pressur previous
contempl model survey support msd-hsd pump volum growth
 pick share remain
respond expect percentag type diabet patient practic
use cgm increas today end decad
within year estim current market penetr
consist forecast cgm volum growth exceed
medicar reimburs overal price come innov new product
libr potenti acceler intens manag type adopt see
key driver robust volum growth
respond expect percentag type diabet patient practic
use cgm increas today end decad
contrari consensu view respond expect percentag intens
manag type patient use cgm grow well ahead
respond believ patient would benefit alert alarm flash
monitor check continu suggest would benefit howev
respond indic benefit justifi premium price
like better question payer vs endocrinologist believ suggest
price sensit could increas market level previous contempl
model
respond project libr cgm share grow next year
libr user expect come fingerstick respond view libr
best suit intens manag type popul accordingli believ
libr catalyz acceler overal market growth year period
market share project go senseon
expect garner share keep mind aforement market penetr
expect annual type popul growth rate view share
project posit vendor
pleas see page report import disclosur
slightli reduc overal volum project due slower expect
ramp fulli captur compani model note survey
prompt us increas longer term volum assumpt
also reduc long term price assumpt reflect survey feedback
aggreg market price declin partial offset volum growth result overal us
cgm market revenu growth
estim continu includ zero contribut broader type opportun
though believ unh/dxcm pilot key potenti catalyst link
reduc revenu estim account guidanc link
longer term price uncertainty/concern base survey result
consensu see page detail revis model assumpt
howev survey result fortifi convict remain cgm market
leader forese futur best product pipelin launch mid
mdi patient industri sustain signific doubl digit volum growth
forese futur
also believ type opportun could drive signific upsid long
term expect near term may remain volatil potenti price uncertainti
yet reflect longer term consensu estim howev continu like stock
long term given current valuat sale consensu begin account
price uncertainti come quarter setup begin improv
help launch
survey result posit support expect compani
diabet franchis return strong growth us year fingerstick
expect libr post us sale increas
could room upsid number particularli libr abl drive
greater market penetr current forecast
importantli beyond diabet repres total sale
expect continu exceed consensu expect post robust top
bottom line growth mani year come remain one top pick
specif cgm see pump even assum lose modest share
next sever year expect continu cgm instal base growth us
forese futur ou like grow faster compani domin pump
franchis commerci scale support growth launch guardian connect
first stand-alone cgm us great growth opportun start
zero expect garner much share among mdi user diabet
sale
respond expect percentag type patient use insulin pump
increas current end decad year
estim current market penetr modestli increas penetr
support continu mid high-singl digit market growth consist prior market
respond expect prior jnj/anima user migrat
given relationship establish suppli patient
anima suppli first crack patient expect slightli number choos
howev anima exit clearli benefit vendor
worth note competit environ soften next
year potenti multipl new entrant expect come market
next year includ bigfoot biomed beta
bionic potenti roch among other
respond expect gain modest share next year
increas similar past survey market share
expect remain stabl vlrx also expect remain stabl
worri
respond expect medicar coverag increas proport patient
choos omnipod mani expect signific doubl digit increas page
survey conduct prior news gain coverag broad coverag
expect part
larg maintain volum forecast primari chang made reflect
exit j/anima exit primarili result higher market share remain
player greatest beneficiari
notabl give much credit reimburs progress
like could base survey feedback may evolv learn
survey result increas convict continu exceed consensu
estim forese futur us omnipod busi could acceler
next year vs current forecast sustain mid-teen growth medicar
reimburs huge catalyst per respond well launch multipl new
product soften competit environ cheap multipl
combin continu upward estim revis robust revenu
growth signific margin expans achiev profit continu
drive stock higher
survey result fortifi confid abil achiev doubl digit diabet
revenu growth next sever year insulin pump share gain driven soften
competit environ expect total us pump instal base growth
driven anima exit commerci scale statu
cgm-autom pump market bolster growth cgm price
uncertainti potenti headwind continu robust instal base growth includ
like faster ou growth keep us confid diabet growth outlook
importantli remain confid overal compani outlook diabet repres
sale
survey result strong consist throughout
survey past sever year see path sustain strong revenu growth
least next year well potenti path cash flow break-even
compani target earlier
howev need financ still compani current attempt address
without clariti recommend own stock updat model
recent strong perform guidanc link see page full
respond tremend enthusiast vlrx market share outlook
said importantli respond expect type patient use insulin
pump next sever year import vlrx remain earli
compani turnaround result solid data point link
ev/ continu like risk/reward
tabl content
compani report cowen compani
compani report cowen compani
pleas see page full market model
conduct survey endocrinologist attempt gain insight
continu glucos monitor cgm insulin pump market competit trend
survey conduct decemb queri respond throughout us
conduct survey qualtric
base number patient treat annual respond estim
survey reach us type popul us intens
within report defin intens manag type patient
progress multipl daili inject insulin basal bolu similar type
patient broader type patient popul type
diet/exercis oral per day insulin estim
intens manag type patient us broader type patient
anoth peopl us prediabet
note type refer intens manag patient
aim address follow key question
near long term growth outlook cgm insulin pump
market us
competit outlook cgm sever new product recent
launch launch next month abt libr dxcm
competit outlook insulin pump market contract
near term j/anima potenti tandem
outlook increas adopt cgm insulin pump
type patient popul next year within intens
manag type cgm broader type patient popul
averag patient per respondenttot us patient populationtyp patient us patient populationtyp cowen
believ number us cgm user grow annual next
year today revenu growth compound-annual-growth-rate
price come time acceler could occur due
multipl new product signific innov libr factori calibration/eas use
type intens manag type patient place overal price come
increas awar cgm first new product signific commerci
invest behind libr mdt guardian connect potenti
worth note includ contribut broader non-
intens type patient popul estim earli clear progress
made excit dxcm pilot program unitedhealthcar link
launch libr true fingerstick replac among advanc softwar
solut glooko other futur catalyst includ result
dxcm/unh pilot among pilot link new product advanc first
averag respond expect cgm penetr among type patient
increas today year year
estim penetr penetr
importantli proport respond view cgm benefici type
patient insulin pump increas third straight survey chose cgm
survey vs may survey survey cgm
penetr among multipl daili inject mdi user still increas
awar benefit cgm cgm first lead robust growth
type background cowen estim estim patient
type diabet us current incid grow annual us cgm
penetr among type patient current
expect increas believ cgm
becom standard care type patient long term
type penetr estim slightli prior annual expect
due entir slightli slower expect medicar launch oper
medicar type penetr expect prior survey/curr
expect though rapid increas still expect page respond
type penetr expect increas today averag median
year year
interestingli respond expect far greater intens manag type
penetr current penetr median expect
increas year year median given size
opportun even modest upsid forecast intens manag type
patient could drive notabl upsid
medicar background cowen estim medicar estim repres
total us type patient total us intens manag
type patient estim type penetr today vs
broader market expect reach
intens manag type estim penetr goe
today ye drive total us
intens manag penetr aggreg estim
repres total us market growth next year
respond expect total number patient decid use abbott
libr next year previous use fingerstick
come real time cgm system dexcom/medtron respond
also view abbott libr best suit intens manag type patient
support view libr acceler overal cgm market growth
libr better current expect upsid like come via
greater market penetr oppos lower patient number dxcm/mdt
put data context current assum patient use libr
end patient came cgm estim
respond would patient within current model
incorpor us attrit patient total across cgm
user switch libr wont come point believ
current forecast captur dynam
major respond believ alerts/alarm benefici type patient
rel flash product like libr though said believ product
alerts/alarm share capabl deserv premium price vs flash product
given physician want lower price broader patient access result arent
terribl surpris believ alerts/alarm share clearli deserv premium
magnitud deserv premium hard determin commerci payer
respond dynam next year import
market trend note meantim abbott today still reimburs
commerci payer accordingli patient use libr outsid pay
pocket cost non-cm patient current
worth note maintain reimburs signific price
premium multipl ou market includ germani assum alerts/alarm
share function effect prevent sever hypoglycem event flash
monitor particularli nighttim wed argu reason assumpt
acut cost argument made well price premium link
case past survey major respond
somewhat posit outlook use intermitt
cgm broader type patient popul next year remain
earli multipl catalyst come next year could begin
acceler adopt build investor confid long term outlook
includ multipl new product dxcm/verili libr outcom
still incorpor broader us type patient popul within market
estim though continu strong convict adopt within
popul question us type patient
tripl number peopl us prediabet massiv opportun
could drive signific long term growth
abt libr current gener buzz investor attent
headlin commerci coverag probabl necessari reach
forecast respond expect gain market share next
year next year expect product success
give libr even credit estim garner
market share howev
import reiter respond expect libr user come
fingerstick oppos real time cgm system respond
averag view product best suit intens manag type patient
popul accordingli expect libr acceler overal market growth cgm
awar long term benefit vendor
set retain market leadership posit believ
best product pipelin industri factori calibr verili product mdi
decis support invest among other respond
believ continu market leader beyond
respond expect share declin current year
year less materi reduct market share current
embed expect estim us share declin
current thereaft market
share reduct next year vs expect respond
start higher market share base respond assum
possess reimburs respond expect clear
market share leader share follow possess
seem high without reimburs
respond expect lose similar amount market share
next year next year though remain second
largest us cgm vendor respond expect share move
current vs estim next year vs
estim year vs estim expect mdt cgm
market posit remain base integr pump system
futur expect launch first us stand-alone cgm
guardian connect dont expect garner much success among mdi patient
check continu suggest guardian clear improv mdt
prior sensor enlit still lag competitor accuraci reliabl eas use
disadvantag seem like increas launch sensor
factori calibr libr add alerts/alarm clear despit
outlook market share declin still expect signific patient volum growth
estim annual us cgm instal base growth next
year also note recent blog post suggest remedi prior sensor
senseon rate expect launch us fulli
implant month wear sensor uniqu respond dont expect
senseon disrupt market share expect next
year expect next year regardless larg mute
respons respond on-going consult check given system
uniqu form factor roch behind investor continu monitor
senseon close speak roch timelin us cgm launch unclear
compani intern market seem primarili focus senseon
respond expect pump penetr among type patient continu
modestli increas current next year
year intens manag type penetr expect increas
current median year median
cowen outlook estim believ continu modest penetr increas
support sustain us insulin pump market growth mid high-singl digit
forese futur estim us type pump penetr increas
current next year within intens
manag type estim penetr increas today
steadili increas annual thereaft estim larg line
prior expect
respond expect market leader gain modest share next
year tandem share expect increas
greatest expect increas among vendor market share remain
steadi among respond past month isnt expect increas
next year though modest increas expect within type patient
vlrx share expect remain steadi among type patient expect
 j/anima expect lose notabl share see anima exit
cowen estim outlook next year subsequ recent
announc j/anima exit market type focus vendor
remain market share share tandem
share tandem need addit financ possibl
market contract next year though current attempt
address financ need howev notabl competit enter
market near term worth mention mani entrant could emerg
potenti roch recent exit us market among other
third consecut survey market share expect
increas howev meantim clearli far outgrown market
grow instal base ultim arent worri
survey conduct prior recent news omnipod gain medicar
coverag broad coverag like part howev ask
respond made clear gain coverag know
would drive significantli pumper choos omnipod
respond said wouldnt chang prior market share forecast
respond expect coverag increas proport patient choos
omnipod mani expect signific doubl digit increas pleas see page
detail
respond expect anima patient move
second greatest expect beneficiari third
remain back pen
background outlook late j/anima announc offici exit
insulin pump market put patient slightli market
grab given posit partner j/anima suppli patient
suppli septemb well commerci scale like
captur major anima patient next year howev vendor
benefit
respond excit potenti hybrid close loop fulli
close loop system expect cgm-autom system drive
inflect type pump penetr anoth say mayb
understand excit dont share respond overwhelm
enthusiasm least first gener system histor barrier broader pump
adopt highlight everi one survey includ one
cost complex appear address first gener system
anyth seem possibl first gener system may increas cost
complex theme hear physician regard also worth note
respond didnt includ inflect penetr forecast instead call
continu modest annual increas
longer term iter expect seamless easi use
solut catalyz broader mdi adopt howev meantim dont expect
materi acceler rel current annual pump market growth msd-hsd
survey result posit market share estim respond
larg line current expect impli signific revenu
growth next sever year estim us libr revenu
approxim potenti grow
off-set continu declin fingerstick busi libr larg displac
time support return strong growth abt us diabet busi
also expect number posit develop next month
includ broad commerci reimburs pediatr indic addit
real time commun develop compani bigfoot biomed
collabor could launch meantim absenc
alerts/alarm share function may limit adopt among current cgm user
plenti non-cgm user go includ type cgm
penetr us far less ou type intens manag penetr
patient expect abbott diabet divis post robust growth
forese futur diabet repres sale
survey result larg posit less excit data point
price although given price concern key driver dxcm stock
under-perform would hard argu surpris overal market
growth market share estim re-affirmed confid current
instal base forecast well potenti instal base upsid
updat model concurr survey account result
guidanc increas long term volum expect reduc
long term revenu forecast better account price uncertainti net result
revenu forecast consensu beyond still impli
signific long term growth believ support long invest
current level revis revenu around midpoint manag
guidanc consensu forecast
consensu howev half sell side model yet
updat guidanc consensu come
revis revenu model assum within total us market dxcm market
share declin
beyond break
medicar assum dxcm medicar market share drop
believ survey
result consult check support maintain clear
leadership market posit within medicar high preval hypoglycemia
unawar increas valu alerts/alarm even recent abbott
us commerci exclud medicar forecast assum us
commerci market share fall
put anoth way exclud medicar current us instal base
forecast assum add net us commerci patient
total new us commerci cgm user expect
unless penetr estim optimist seem leav
room upsid even rel increas volum forecast
price assum annual revenu per patient across entir
instal base declin
would repres fulli dispos day
sensor price zero transmitter/receiv revenu
believ bia upsid rel instal base forecast especi
consid next gener factori calibr sensor
expect launch around latest
retain best-in-class accuracy/reli improv day perform
close gap eas use benefit libr current differenti factori
calibr eas insert slim profil etc
price clearli uncertainti resid believ revis forecast
captur uncertainti downsid risk potenti downsid remain
believ real time cgm accur alerts/alarm share function clearli
deserv premium price flash monitor howev much premium
higher remain question mark today like answer payer
next year survey result support materi long term
price premium aim survey wasnt address question high
level believ stock risk less mani bear argu due fact even
downsid price scenario come fruition still best
technolog rapidli grow market rebas lower level revenu
growth outlook would compel revenu growth acceler closer cgm
patient growth addit market specif estim includ
broader type popul adopt may take potenti
near medium term catalyst notabl result pilot
unitedhealthcar doesnt take much adopt within massiv broader type
market opportun drive signific growth
near term stock narr seem like continu focus abbott libr
headlines/fear longer term price uncertainti stand-alone launch anoth
headlin howev survey demonstr libr fear market share
perspect like overblown launch factori calibr sensor
fortifi convict dxcm leadership posit price uncertainti
consensu model begin incorpor uncertainti revis model
stock setup could begin improv next coupl quarter aid
launch/verili progress/unh pilot updat take longer term view
best technolog cgm expect becom standard care type
patient ultim penetr entir spectrum diabet care expect
volatil persist near medium term board long term
believ could start break rang clear believ
share work long term price assumpt need come sell side model
need demonstr strong volum growth pipelin progress
also improv oper disciplin
view survey posit survey result suggest abl
least meet diabet revenu growth expect next sever year
given signific share posit commerci clout near term differenti
cgm-autom pump soften pump market competit
environ least expect remain clear pump market
leader forese futur
context impact anima assum mdt us pump instal base
increas annual assum captur anima
pumper late total opportun anima patient
would repres total us instal base growth forecast
greatest near term upsid potenti forecast pump market
contract tandem could put anoth market
longer term competitor come market bigfoot beta bionic
potenti roch other rest market launch
cgm-autom solut expect lose share howev even assum share
loss expect solid msd us pump instal base growth forese futur
higher growth next year ou continu cgm
improv increasingli import driver mdt pump busi
within cgm expect enter stand-alone segment first time via
launch guardian connect sensor tout sugar iq
softwar develop conjunct differenti howev expect
instal base growth within cgm remain driven mdt pump market domin
rel stand-alone cgm competitor check continu indic guardian
lag competitor accuracy/reli eas use top driver
physician recommend per survey cost accordingli
dont expect garner materi market share among mdi patient first
gener product regardless stand-alone segment repres attract
growth opportun start zero even without materi mdi
market share expect annual us cgm instal base growth next
seem unlik immun expect broad cgm market price
pressur next year howev upsid potenti instal
base forecast cgm adopt among mdt pumper move faster expect
and/or broader type adopt begin come fruition given state ou
penetr ou growth us level accordingli cgm price
outlook creat error bar remain comfort forecast sustain
doubl digit diabet revenu growth especi consid
under-penetrated ou market diabet repres mdt sale
view survey result posit support expect
post upsid rel revenu expect forese futur
base case alreadi consensu expect recent posit
reimburs develop increas odd upsid case describ
detail could drive signific stock appreci
respond market share forecast neutral
recur theme within survey despit consist
gain share market respond view medicar reimburs
huge catalyst market share among patient overal market share
estim provid prior recent news gain coverag
broad coverag expect start
current forecast podd us instal base grow exit
market share market share
market share mid-teen annual instal base growth result annual us
omnipod revenu growth next year overal modest upsid
consensu expect
believ upsid case grow us instal base annual
result us omnipod revenu growth next year would result
upsid current us omnipod revenu forecast get
aw close target get level instal base
growth assum chang current pump penetr estim
instead increas market share vs base case
vs base case upsid case ambiti though set launch
multipl new product next year dash horizon concentr
insulin significantli increas market access medicar soften
competit environ anima potenti tandem achiev
us growth outlook coupl revenu growth ou
aid materi price accret move distribut direct provid
clear path exceed consensu estim neulasta biosimilar launch
us repres potenti drug deliveri revenu headwind begin late
one believ alreadi fulli reflect within model forecast
annual neulasta onpro revenu declin begin potenti upsid
catalyst intern launch much longer term new partner product progress
revenu stock perspect even new competit next year
bigfoot biomed beta bionic other imped upon
upsid case growth beyond meantim
clear headwind podd us growth and/or neg catalyst accordingli even
rich revenu multipl continu like risk/reward current level
certainli revenu stori robust margin expans profit
come remain top diabet devic pick
consist everi survey weve ever done expect gain market share
among respond physician patient love tndm product
product pipelin solid pois becom first non-mdt pump
market cgm-autom plg hybrid close loop
proprietari infus set pois drive signific revenu growth
howev stock perspect imposs isol strong fundament
trend signific balanc sheet uncertainti like cash hand last
best situat lost investor
essenti left dead investor convers howev tandem
recent initi effort access financ could last
accordingli possibl stay around longer peopl expect
abl secur suffici financ see plausibl albeit easi
path oper cash flow break-even compani target
know mayb surpris everyon time tell separ also updat
model pre-announc page increas revenu
slightli increas revenu
respond didnt expect vlrx gain share type pumper next
year howev still view survey posit vlrx respond
expect penetr pump among type patient continu increas
solid clip key underli market driver vlrx revenu growth
compani go patient alreadi use tradit type insulin pump
given small base vlrx grow posit earli sign
compani commerci re-organ expans result anoth
encourag data point continu believ vlrx grow revenu
significantli next year view long term risk/reward posit
expect near term new product link prefil intern
expans could drive upsid rel model
ask benefici type patient glycem control
hypoglycemia patient qualiti life insulin pump cgm respond
chose cgm chose pump respond choos cgm
survey respond may demonstr
awar benefit cgm grow rapidli still signific room
awar grow penetr cgm much higher today
figur could choos one cgm insulin pump devic believ
benefici type diabet patient glycem control hypoglycemia patient qualiti
averag respond expect penetr type patient increas
today year year repres steadi
level signific increas note penetr within respond
market estim us penetr exit henc
may posit bia within survey direct posit
also encourag respond expect start new patient
cgm/fgm vs expect add rel may
survey almost doubl proport respond chose patient
figur proport type patient current use
cgm expect next
figur expect start patient cgm/fgm
month significantlyless less moderatelyless samey moderatelymor cowen
estim us type patient popul within
medicar us intens manag type popul
respond expect penetr type patient reach
next year next year year estim
current forecast penetr well broader
type penetr expect respond next year
note within may survey respond expect penetr reach
year ahead estim despit much lower start point
respond patient current use cgm within may survey
accordingli result wors expect past survey consult
convers continu give us confid type penetr catch
broader market rate next year pent demand
high clinic valu hypoglycemia awar correl diabet durat
importantli respond expect intens manag type adopt
well forecast averag respond expect penetr reach
next year vs current estim
intens manag type patient popul close doubl type opportun
penetr upsid could meaning time
figur proport type medicar age patient
current use cgm expect
figur proport intens manag type medicar
age patient current use cgm expect
year
proport respond chose somewhat posit aggreg
overwhelm believ posit data point remain
excit longer term adopt outlook
multipl catalyst upcom next year potenti
begin increas adopt intermitt cgm use among broader non-insulin use
type patient includ new product like heavi commerci invest
dexcom/verili abbott perhap importantli
recent announc pilot unitedhealthcar
pilot includ type patient plan util real time cgm data
like data like activ provid patient physician
coach provid lifestyl recommend patient chang diet
exercis etc optim medic drug patient
use per possibl time approach save system billion
dollar mani mani live success result pilot could lead
launch program broadli across membership base
figur statement best describ view use intermitt cgm broader
type patient popul next year
consist prior expect libr strong market entrant
quickli grab meaning market share market expans seen
follow page howev expect remain market leader
survey result along dxcm best-in-class product pipelin lead us believ
market share estim could conserv
assess futur market share expect ask respond assum
launch factori calibr sensor end line
guidanc abbott libr pocket cost patient less
dexcom/medtron differ pocket cost patient
assum averag patient pay total cost pocket
abbott libr gain broad us reimburs current pocket current
price dexcom/medtron remain current level modestli declin
backdrop respond expect libr gain market share
cgm/fgm user next year next year
expect lose share next year current estim
us share loss interestingli expect lose much
share beyond next year estim total us share loss
expect lose market share among
respond patient next year anoth year
previous expect respond view nich vendor
note yet launch us
figur proport cgm user current use follow product
expect year year pleas assum follow end
launch factori calibr sensor abbott libr
pocket cost patient less dexcom/medtron
respond expect vast major patient use libr next
year previous use fingerstick libr user
minor user come patient alreadi use real time cgm system like
accordingli remain confid expect acceler market growth
launch libr patient convert interstiti monitor
fingerstick upsid current libr estim us patient
year end year end appear like come higher market
penetr oppos lower dxcm/mdt patient estim
figur patient expect use abbott libr next year proport
believ previous use follow glucos measur
fromfingerstickscom rtcgm cowen
survey particularli time given abbott libr gain
reimburs januari cgm medicar
reimburs visibl today limit still hurdl
proceed dose claim seem like pursu reimburs
well point next year regardless like remain
next year assum reimburs
respond expect maintain clear leadership posit share
larg line longer term expect howev specif
estim hold share cgm user year end given modest
head start vs like alreadi patient year end increas
valu real time cgm alerts/alarm share possess medicar age patient
among greater averag preval hypoglycemia unawar
share current allow medicar expect chang
note respond chose share level
share seem unlik without reimburs patient pay
pocket popul though signific share seem reli
cash pay reimburs competitor sad like attain
reimburs point next coupl year
figur assum abbott reimburs proport medicar age
cgm user expect use follow product next year
respond said type patient would benefit alerts/alarm
fgm libr also note patient median would prefer
alert alarm
admittedli expect result favor benefit alerts/alarm materi
said believ may confus among respond
answer question seem unlik endocrinologist would believ
patient could benefit alerts/alarm and/or patient
would prefer alerts/alarm regardless take respons face
valu support libr market share estim
figur proport type patient believ would
benefit alerts/alarm vs flash monitor libr
figur proport patient believ would prefer
alerts/alarm
slightli less half respond said product alerts/alarm
share capabl deserv premium price expect
howev context physician desir access lower price
result arent surpris
figur believ product alerts/alarm share capabl deserv premium
price vs without alerts/alarm libr
consist histor survey work third survey row ask
patient popul libr best suit rel real time cgm intens
manag type patient option chosen often follow
type distant third fourth basal type per day insulin
non-insulin use type
figur patient popul believ abbott libr best suit rel real
case everi cgm survey weve done accuraci number
driver physician recommend eas use number
follow cost reliabl integr insulin pump
figur import factor drive patient choic cgm/fgm
view result posit accur
product market abbott like simple/easi use current though
aim close gap factori calibr sensor around
includ new insert system highlight accuraci data current
commerci soon commerci product
fda safeti summari effect data compani report cowen compani
factor drive recommend insulin support profil day warm adult overal adult overal calibr day libr us longer warm time studi design yield better result eu calibr per daili daili daili daili daili calibr enlit time daili calibr calibr time per time daili calibr calibr time per time daili calibr calibr time per time daili calibr calibr time per calibr time per day calibr time per day cowen
respond expect pump penetr among type patient continu
modestli increas next year believ continu
penetr increas well modest type penetr increas support
continu msd-hsd overal us pump market growth expect futur price
remain consist current level
believ respond nation averag us pump penetr
estim penetr current approxim us type patient
us intens manag type patient
figur proport type patient current use
insulin pump expect
figur proport type patient intens insulin
regimen use pump expect
vast major respond expect first gener hybrid close loop
close loop system drive inflect penetr pump among type
patient next year anoth repli mayb
respond said ask system excit
often chosen signific margin follow tandem
figur believ launch first gener hybrid close loop
 close loop system drive inflect
penetr pump among type patient next
figur cgm-autom insulin deliveri platform
excit check appli
perhap temper optim tradit barrier pump
adopt exist sever year remain complex pump
remain signific barrier point appear like increas first
gener cgm-autom product seem fall categori believ
time compani develop solut focu simplic patient
caregiv success
figur believ import barrier put type patient
pump check appli
horizonbigfoot biomedicalbeta bionicsbarri therapi respondentsout pocket support system readi compli w/proper pump train support close loop insulin dose effect reliabil cgm pump cowen
across type type next page patient market leader expect
gain modest share alreadi market share posit driven
continu statu cgm-autom product market
first crack jnj/anima patient largest commerci scale
respond expect gain share next year
compani solid product pipelin plg use expect launch
hybrid close loop product use typezero expect
launch also biggest non-mdt beneficiari
jnj/anima exit howev need access financ next month
remain busi compani unabl market could
grab obvious downsid risk repres un-model
sourc potenti signific upsid note
probabl better chanc surviv and/or last longer mani expect though
may function pretti low bar
oddli enough third survey row gain share among
respond outlook larg neutral given podd us instal base like
increas higher guidanc left compani
clearli gain share continu believ well posit continu
grow faster market next sever year tubeless option new
product increas commerci invest soften competit landscap
worri survey result
potenti competit entrant horizon next year includ bigfoot
cellnovo potenti roch re-entri hybrid close loop
figur proport type pumper current use follow product
expect year
 announc earli compani would explor strateg
altern anima busi octob decis made
offici exit pump busi us canada chosen
partner provid transit patient provid anima suppli
patient septemb upon time anima suppli longer
avail given arrang first crack anima patient
come warranti late anima like patient use pump
us slightli less total market share
respond expect greatest beneficiari develop
anima user follow
also worth note potenti upsid unabl
access addit financ move anima market
follow would remain competitor
horizon said believ better shot surviv and/or last
longer mani investor expect
figur j/anima recent announc plan exit insulin pump busi
patient current use anima proport believ choos follow
pen cowen
ask respond question prior recent news
elig medicar reimburs via part expect possess broad
coverag begin estim us type patient within
medicar previous commerci insulin pump without
medicar coverag also worth note medicar coverag help
expand medicaid coverag estim decis help access
survey data receiv medicar coverag know
respond would expect significantli higher proport patient
use omnipod potenti catalyst among strong underli fundament
worri headlin market share result survey
figur omnipod receiv medicar coverag would significantli chang proport
type pumper expect use insulet/omnipod next year
morey morey morey morey cowen
check kol continu suggest product design type patient
mind focu simplicity/eas use best posit among
patient popul long term howev tradit type vendor continu
domin still nascent penetr market respond expect
continu next year expect
gain share expens jnj/anima exit market result vlrx
current commerci type target pump neutral
interest see market evolv next year multipl
new competit solut come market includ patch pump
decis support tool via bluetooth enabl pens/cgm eli
figur proport type patient activ use pump use follow product
expect year
cowen compani
market overviewtot diabet diagnos ensiv ensiv insulin growth type manag type mng type type diabet diagnos total diagnos insulin penetr growth adult total pumper penetr growth pediatr total pumper growth depend type inject multipl per type insulin ensiv insulin growth diabet devic market model insulin deliveri cowen
cowen compani
markettot market user period growth intens manag exist renew patient instal base vendor beta bionic otherspati instal base share vendortot exit market septemb beta bionic othersu diabet devic market model insulin share cowen
cowen compani
market overviewtot diabet diagnos ensiv total cgm ensiv insulin growth cgm cgm type manag type cgm mng type diabet diagnos total diagnos glucos monitor penetr total total cgm growth cgm inject multipl per day continu glucos monitor penetr mdi type cgm user continu glucos monitor penetr type cgm user ensiv manag type total type ensiv insulin segment growth cgm inject multipl per day mdi cgm penetr type cgm user insulin cgm penetr type cgm user us diabet devic market model glucos monitor cowen
cowen compani
marketcgm userstot cgm user period assum zero contribut fromgrowth insulin use patient drive signific upsid long intens manag forecast patient share entri roch other ltpatient abbott- /other- us diabet devic market model continu glucos monitor share cowen
compani report thomson eikon cowen compani
mm except per share end previou rang profit end previou guidanc gener oper y/i per cowen
compani report thomson eikon cowen compani
mm except cagrcommentstot profit gross margin achiev pump market share current growth similar plu increment clinic trial mileston oper non-cash stock compincrement aother interest earn per cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
